| scholarly article | Q13442814 |
| P50 | author | Jo Caers | Q40481275 |
| Yves Beguin | Q87600691 | ||
| Nadia Withofs | Q88220590 | ||
| François Cousin | Q89870708 | ||
| Roland Hustinx | Q102068106 | ||
| Bernard De Prijck | Q114407466 | ||
| P2093 | author name string | Sanjiv S Gambhir | |
| Christophe Bonnet | |||
| P2860 | cites work | αV integrins in angiogenesis and cancer | Q26851768 |
| 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression. | Q34205400 | ||
| Integrins and bone metastasis: integrating tumor cell and stromal cell interactions | Q34441622 | ||
| International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma | Q34450381 | ||
| The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective | Q36673465 | ||
| Biological aspects of angiogenesis in multiple myeloma. | Q37956524 | ||
| Radiolabelled RGD peptides for imaging and therapy | Q37990409 | ||
| Detection of osseous metastasis by 18F-NaF/18F-FDG PET/CT versus CT alone. | Q38241575 | ||
| Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. | Q38311815 | ||
| Avβ3 integrin: Pathogenetic role in osteotropic tumors. | Q38540840 | ||
| Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group | Q39214847 | ||
| Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases | Q39565634 | ||
| Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells | Q40147550 | ||
| Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma | Q40232283 | ||
| The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model | Q40330087 | ||
| Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via αvβ3 integrin in myeloma cells | Q42255958 | ||
| Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. | Q46086896 | ||
| 18F-FPRGD2 PET/CT imaging of integrin αvβ3 in renal carcinomas: correlation with histopathology | Q46477526 | ||
| Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. | Q48089815 | ||
| [(18)F]FPRGD2 PET/CT imaging of integrin αvβ3 levels in patients with locally advanced rectal carcinoma. | Q50553926 | ||
| ¹⁸F-FPRGD₂ PET/CT imaging of musculoskeletal disorders. | Q52926003 | ||
| Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting | Q78143346 | ||
| Fully automated preparation and conjugation of N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) with RGD peptide using a GE FASTlab™ synthesizer | Q83299314 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 6162845 | |
| P577 | publication date | 2017-07-27 | |
| P1433 | published in | Contrast Media & Molecular Imaging | Q2995750 |
| P1476 | title | A First Report on [18F]FPRGD2 PET/CT Imaging in Multiple Myeloma | |
| P478 | volume | 2017 |
Search more.